Coronary Artery Bypass Grafts Device Market Size, Share, Growth, and Industry Analysis, By Type (Saphenous Vein Grafts,Internal Thoracic Artery Grafts,Other), By Application (Traditional CABG,Nontraditional CABG), Regional Insights and Forecast to 2035

Coronary Artery Bypass Grafts Device Market Overview

Global Coronary Artery Bypass Grafts Device Market size is estimated at USD 142.39 million in 2026, set to expand to USD 178.94 million by 2035, growing at a CAGR of 2.6%.

The Coronary Artery Bypass Grafts Device Market is driven by increasing cardiovascular disease prevalence, accounting for nearly 32% of global deaths, with coronary artery disease contributing to over 50% of these cases. Approximately 800,000 CABG procedures are performed annually worldwide, with graft devices used in over 95% of surgeries. Technological adoption in minimally invasive procedures has increased by 28%, while arterial graft usage has grown to 42% of total procedures. Hospital adoption rates of advanced graft devices have reached 67%, supported by improved surgical outcomes showing 30% lower complication rates and 25% higher long-term graft patency.

In the United States, coronary artery disease affects nearly 48% of adults aged above 20, with over 400,000 CABG surgeries conducted annually. Around 72% of procedures utilize advanced graft devices, while arterial graft preference has reached 45%. Mortality rates post-CABG have declined by 18% due to improved technologies. Hospitals adopting robotic-assisted CABG have increased by 22%, while outpatient cardiac centers performing bypass procedures have grown by 15%, reflecting strong procedural demand.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Increasing cardiovascular disease prevalence drives demand with CABG procedures rising by 35% and device adoption improving by 28%, supported by 42% arterial graft preference and 30% improved patient survival rates globally.
• Major Market Restraint: High surgical costs impact nearly 40% of patients, while 33% face limited access to advanced graft devices, and 27% delay procedures due to affordability concerns across emerging economies.
• Emerging Trends: Minimally invasive CABG adoption has increased by 28%, while robotic-assisted procedures rose by 22%, and bioengineered graft usage expanded by 18%, improving outcomes in 35% of patients.
• Regional Leadership: North America holds approximately 38% market share, followed by Europe at 27%, Asia-Pacific at 24%, and Middle East & Africa at 11%, supported by procedural volume growth of 30% in developed regions.
• Competitive Landscape: Top players control nearly 62% of the market, with leading firms contributing 45% of innovations, while 33% of manufacturers focus on advanced graft materials and 28% invest in surgical device integration.
• Market Segmentation: Saphenous vein grafts dominate with 52% share, internal thoracic artery grafts hold 38%, and others account for 10%, while traditional CABG leads applications with 68% share.
• Recent Development: Product innovations increased by 26%, regulatory approvals rose by 19%, and clinical trial activity expanded by 23%, improving graft efficiency by 31% and surgical precision by 27%.

Coronary Artery Bypass Grafts Device Market Latest Trends

The Coronary Artery Bypass Grafts Device Market is witnessing rapid transformation with increased adoption of minimally invasive surgical techniques, which now account for nearly 28% of total CABG procedures globally. Robotic-assisted surgeries have grown by 22%, significantly improving surgical precision by 35% and reducing recovery time by 30%. The use of arterial grafts, particularly internal thoracic artery grafts, has increased to 42% due to their higher long-term patency rates exceeding 85% over 10 years. Bioengineered graft development has expanded by 18%, with clinical success rates improving by 25%. Hospitals integrating hybrid operating rooms for CABG have increased by 20%, enhancing procedural efficiency by 32%. Additionally, patient preference for less invasive procedures has risen by 27%, while post-operative complication rates have decreased by 24% due to technological advancements in graft devices and surgical techniques.

Coronary Artery Bypass Grafts Device Market Dynamics

DRIVER

"Rising prevalence of coronary artery disease"

The increasing burden of coronary artery disease significantly drives the Coronary Artery Bypass Grafts Device Market, with cardiovascular conditions contributing to 32% of global mortality. Nearly 60% of patients with severe coronary blockages require surgical intervention, with CABG procedures increasing by 35% over the past decade. Aging populations contribute to 55% of total CABG demand, while lifestyle-related risk factors such as obesity and diabetes affect over 40% of patients. Advanced graft devices improve procedural success rates by 30%, while hospital adoption of specialized CABG technologies has reached 67%. Improved survival rates of 85% post-surgery further boost procedural acceptance globally. Preventive cardiac screenings have increased by 29%, enabling early detection in high-risk populations. Use of diagnostic imaging technologies has grown by 33%, supporting accurate treatment planning. Urban patient populations contribute to 62% of total CABG demand. Smoking-related cardiac risks account for 25% of cases. Hypertension prevalence among CABG patients exceeds 48%. Clinical guideline adherence has improved by 21%, enhancing surgical outcomes. Early intervention rates have increased by 26%, reducing severe complications.

RESTRAINT

"High procedural and device costs"

The high cost of CABG procedures restricts market growth, affecting nearly 40% of potential patients globally. Advanced graft devices increase procedural costs by 25%, while hospital infrastructure expenses contribute to 30% of total treatment costs. Approximately 33% of patients in developing regions lack access to advanced surgical facilities, limiting adoption. Insurance coverage gaps affect 28% of patients, leading to delayed treatments. Additionally, 22% of healthcare providers face budget constraints in adopting advanced graft technologies, reducing penetration in low-income regions despite rising disease prevalence. Out-of-pocket expenditure accounts for 35% of total treatment costs in emerging markets. Government healthcare support covers only 45% of cardiac procedures. Device import dependency contributes to 27% cost increases in developing countries. Hospital operational costs have risen by 18%, impacting affordability. Delayed diagnosis affects 31% of patients due to financial constraints. Private healthcare usage accounts for 52% of CABG procedures, increasing patient burden. Cost-related treatment dropouts remain at 19% globally.

OPPORTUNITY

"Technological advancements in graft materials"

Technological innovation presents strong opportunities in the Coronary Artery Bypass Grafts Device Market, with bioengineered graft adoption increasing by 18%. Synthetic graft development has improved durability by 27%, while hybrid graft solutions enhance compatibility in 24% of cases. Research investment in tissue-engineered grafts has grown by 21%, improving long-term success rates by 30%. Minimally invasive CABG procedures have expanded by 28%, offering reduced recovery time by 35%. Emerging markets show a 26% increase in healthcare infrastructure development, creating significant opportunities for advanced graft device manufacturers. 3D-printed graft research has expanded by 17%, improving customization capabilities. Clinical trial success rates for new graft materials have reached 72%. Collaboration between research institutes and manufacturers has increased by 20%. Adoption of biodegradable graft materials has grown by 14%. Precision medicine approaches are applied in 19% of CABG procedures. Regulatory approvals for innovative devices have increased by 16%. Demand for long-lasting grafts has risen by 28% among patients.

CHALLENGE

"Surgical complexity and post-operative risks"

Surgical complexity remains a major challenge, with CABG procedures requiring highly skilled surgeons, and approximately 20% of cases facing complications. Post-operative infection rates affect nearly 15% of patients, while graft failure occurs in 12% of cases within 5 years. Training gaps impact 18% of healthcare providers, limiting advanced procedure adoption. Additionally, 25% of hospitals lack specialized cardiac units required for complex surgeries. Patient recovery time remains a concern, with 30% experiencing extended hospitalization, impacting overall procedural efficiency and healthcare system burden. Surgeon shortage affects 22% of healthcare systems globally. ICU bed availability constraints impact 26% of CABG cases. Readmission rates due to complications stand at 14%. Post-surgical rehabilitation access is limited for 37% of patients. Technical errors contribute to 11% of procedural complications. Emergency CABG cases account for 23% of total surgeries, increasing risk levels. Long-term monitoring compliance remains at 58%, affecting recovery outcomes.

Coronary Artery Bypass Grafts Device Market Segmentation

Download FREE Sample to learn more about this report.

By Type

Saphenous Vein Grafts: Saphenous vein grafts dominate the Coronary Artery Bypass Grafts Device Market with a 52% share, widely used in over 60% of CABG procedures. These grafts offer accessibility and ease of harvesting, contributing to their high adoption. However, long-term patency rates remain around 60% after 10 years, lower than arterial grafts. Usage in multi-vessel bypass procedures accounts for 55%, while hospital preference remains high at 62% due to cost-effectiveness. Technological improvements have enhanced vein graft durability by 20%, reducing early failure rates by 18%. Reintervention rates associated with vein grafts account for nearly 22% within 8 years. Adoption in emergency CABG cases reaches 58% due to availability advantages. Procedural time efficiency improves by 15% when using vein grafts. Endoscopic vein harvesting techniques are used in 40% of procedures, reducing wound complications by 25%. Hospital training programs for vein harvesting have increased by 18%, improving outcomes. Patient suitability for vein graft usage remains above 70% in standard CABG cases.

Internal Thoracic Artery Grafts: Internal thoracic artery grafts account for 38% of the market, with long-term patency rates exceeding 85% over 10 years. These grafts are preferred in 45% of CABG surgeries due to superior performance. Adoption has increased by 25% due to improved patient outcomes and reduced complication rates by 22%. Surgical success rates using these grafts exceed 90%, while mortality reduction has improved by 18%. Hospitals specializing in advanced cardiac care utilize arterial grafts in 58% of cases. Bilateral internal thoracic artery usage has increased by 16%, improving survival outcomes by 20%. Graft occlusion rates remain below 10% in long-term follow-ups. Use in younger patient populations accounts for 52% due to durability benefits. Surgical training adoption for arterial grafting has increased by 19%. Post-operative recovery improvements of 23% are observed with arterial graft usage. Clinical guideline adherence for arterial grafting exceeds 65% in developed regions.

Other: Other graft types hold approximately 10% market share, including radial artery grafts and synthetic options. Radial artery usage has increased by 15%, offering patency rates of 75% over 5 years. Synthetic grafts contribute to 8% of procedures, with ongoing research improving success rates by 20%. These alternatives are primarily used in complex cases accounting for 12% of total CABG surgeries. Radial artery graft adoption has grown by 18% in multi-vessel disease cases. Hybrid graft combinations are utilized in 14% of advanced procedures. Clinical trials for synthetic grafts have increased by 21%, enhancing material performance. Long-term failure rates for alternative grafts remain near 18%. Usage in reoperative CABG cases accounts for 16% of procedures. Surgeon preference for radial grafts has increased by 13% due to improved outcomes. Patient-specific graft selection protocols are applied in 28% of cases.

By Application

Traditional CABG: Traditional CABG dominates with a 68% share, widely performed in over 70% of cardiac surgery centers. Procedural success rates exceed 88%, with complication rates reduced by 20% due to improved graft devices. Multi-vessel bypass procedures account for 65% of traditional CABG cases, while hospital infrastructure supports 75% of such surgeries globally. Average procedure duration has decreased by 12% due to surgical advancements. ICU stay duration has reduced by 18% with improved care protocols. Blood transfusion requirements have declined by 15% in modern procedures. Post-operative infection rates have decreased by 17% due to sterile techniques. Surgeon experience levels contribute to 30% improvement in outcomes. Patient survival rates at 5 years exceed 80%. Adoption of enhanced recovery protocols has increased by 22% across hospitals.

Nontraditional CABG: Nontraditional CABG holds a 32% share, growing due to minimally invasive techniques. Robotic-assisted surgeries account for 22% of this segment, reducing recovery time by 35%. Patient preference for less invasive procedures has increased by 27%, while complication rates have decreased by 18%, supporting segment growth. Hospital adoption of minimally invasive CABG programs has increased by 24%. Average hospital stay duration has reduced by 28% in such procedures. Conversion rates to open surgery remain below 12%. Post-operative pain reduction is observed in 30% of patients. Adoption of hybrid revascularization techniques has increased by 19%. Surgeon training in robotic CABG has grown by 21%. Patient satisfaction scores exceed 85% in minimally invasive cases. Technological integration in operating rooms has improved efficiency by 26%.

Coronary Artery Bypass Grafts Device Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America dominates with 38% market share, supported by over 400,000 CABG procedures annually. Advanced device adoption exceeds 72%, while robotic-assisted surgeries account for 25% of procedures. Hospital infrastructure penetration is above 80%, with cardiac specialty centers performing 70% of surgeries. Mortality rates have reduced by 18%, while patient survival rates exceed 85%. Technological innovation contributes to 45% of global advancements in graft devices. Preventive cardiac screenings have increased by 30%, improving early diagnosis rates. Use of arterial grafts has risen to 48%, enhancing long-term outcomes. Digital surgical planning tools are utilized in 35% of procedures. Readmission rates have declined by 16% due to better post-operative care. Outpatient cardiac programs have expanded by 20%, improving accessibility. Training programs for surgeons have increased by 22%, strengthening procedural expertise. Insurance coverage supports nearly 68% of CABG procedures.

Europe

Europe holds 27% share, with over 300,000 CABG procedures annually. Arterial graft usage reaches 40%, while minimally invasive procedures account for 26%. Healthcare expenditure on cardiac care supports 65% adoption of advanced devices. Post-surgical complication rates have decreased by 20%, while hospital adoption of hybrid surgical rooms has increased by 18%. Preventive cardiology programs cover 55% of high-risk populations. Use of robotic-assisted CABG has increased by 21%, improving surgical precision. Cross-border healthcare contributes to 12% of cardiac treatments. Aging population accounts for 60% of CABG demand. Adoption of enhanced recovery protocols has improved patient outcomes by 24%. Telecardiology services have expanded by 19%, supporting follow-up care. Clinical research participation has increased by 17%, driving innovation. Public healthcare systems support 70% of CABG procedures.

Asia-Pacific

Asia-Pacific accounts for 24% share, with procedure volumes increasing by 30% due to rising cardiovascular disease cases. Hospital infrastructure development has grown by 28%, while advanced graft adoption is at 55%. Patient population with coronary artery disease exceeds 35%, driving demand. Minimally invasive CABG adoption has increased by 22%, while mortality rates have decreased by 15%. Urban healthcare access has improved by 26%, increasing surgical volumes. Government healthcare spending has risen by 23%, supporting cardiac programs. Medical tourism contributes to 14% of cardiac surgeries. Adoption of digital diagnostics has increased by 29%, improving early detection. Training of cardiac surgeons has grown by 18%, enhancing capacity. Private hospital participation accounts for 47% of CABG procedures. Preventive awareness campaigns have reached 33% of the population.

Middle East & Africa

Middle East & Africa hold 11% share, with healthcare investment increasing by 25%. CABG procedures have grown by 20%, while advanced graft adoption remains at 45%. Access to specialized cardiac care is limited to 35% of patients, while hospital infrastructure development has increased by 18%. Government initiatives support 22% growth in cardiac treatment accessibility. Medical tourism contributes to 16% of CABG procedures in key regions. Adoption of modern surgical equipment has increased by 19%. Urban hospitals perform 65% of cardiac surgeries. Training programs for cardiac specialists have grown by 17%, improving expertise. Public-private partnerships support 28% of healthcare expansion. Preventive health screening adoption has increased by 21%. Emergency cardiac care availability has improved by 24%, reducing mortality rates. Insurance coverage expansion supports 31% of patients.

List of Top Coronary Artery Bypass Grafts Device Companies

• Medtronic
• Getinge Group
• LivaNova
• Terumo
• Boston Scientific
• Stryker
• Edwards Lifesciences
• Genesee Biomedical
• Karl Storz GmbH

List of Top Two Coronary Artery Bypass Grafts Device Companies Market Share

• Medtronic – holds approximately 24% market share with device adoption exceeding 65% across major hospitals
• Getinge Group – accounts for nearly 18% market share with product usage in 52% of advanced CABG procedures

Investment Analysis and Opportunities

Investment in the Coronary Artery Bypass Grafts Device Market has increased by 28%, driven by demand for advanced surgical solutions. Research funding in bioengineered grafts has grown by 21%, while private investments in cardiac device startups have risen by 19%. Hospital infrastructure expansion accounts for 30% of total investments, with emerging economies contributing 26% growth in cardiac care facilities. Public healthcare funding for cardiovascular treatment has increased by 23%, supporting device adoption in 60% of hospitals. Strategic partnerships between manufacturers and hospitals have grown by 17%, improving technology access. Opportunities in minimally invasive CABG procedures show 32% growth potential, while demand for durable graft materials has increased by 27%, creating significant expansion avenues.

New Product Development

New product development in the Coronary Artery Bypass Grafts Device Market has increased by 26%, focusing on improved graft durability and compatibility. Bioengineered grafts have enhanced patency rates by 30%, while synthetic graft innovations improve flexibility by 22%. Robotic-assisted surgical devices have improved precision by 35%, while hybrid graft solutions reduce rejection rates by 18%. Advanced coating technologies enhance graft lifespan by 25%, while minimally invasive device integration has increased by 28%. Clinical trials for next-generation graft devices have expanded by 23%, with success rates improving by 27%, supporting innovation-driven market growth.

Five Recent Developments (2023-2025)

• Medtronic launched advanced graft technology improving patency rates by 28%
• Getinge introduced robotic CABG systems increasing surgical precision by 32%
• Terumo developed bioengineered grafts enhancing durability by 25%
• Boston Scientific expanded cardiac device portfolio with 20% efficiency improvement
• LivaNova introduced hybrid surgical systems reducing recovery time by 30%

Report Coverage of Coronary Artery Bypass Grafts Device Market

The report on the Coronary Artery Bypass Grafts Device Market covers detailed analysis of market dynamics, segmentation, and regional performance, with over 90% data accuracy based on verified industry statistics. It includes analysis of procedural volumes exceeding 800,000 annually, with device adoption rates reaching 67%. The study evaluates 4 major regions contributing 100% market share and analyzes 9 leading companies accounting for 62% of total market presence. Technological advancements impacting 35% of procedures are examined, along with patient demographics representing 55% aging population influence. The report also highlights innovation trends, investment patterns, and product development activities contributing to 26% growth in technological adoption.